Neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study

Basit Öğe Kaydı
dc.contributor.authorKarcı, Ebru
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBayram, Buket
dc.contributor.authorCelayir, Melisa
dc.contributor.authorÖzyurt, Neslihan
dc.contributor.authorOyan Uluc, Başak
dc.contributor.authorEken, Aynur
dc.contributor.authorBaşaran, Gül
dc.contributor.authorDemirci, Umut
dc.contributor.authorKemal, Yasemin
dc.contributor.authorOruncu, Mehmet Berk
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorErtürk, İsmail
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorÇelik, Serkan
dc.contributor.authorTürkel, Alper
dc.contributor.authorAlkan, Ali
dc.contributor.authorSakin, Abdullah
dc.contributor.authorCan, Orçun
dc.contributor.authorGünaldı, Meral
dc.contributor.authorEsin, Ece
dc.contributor.authorYıldız, Özcan
dc.date.accessioned2024-10-23T05:32:42Z
dc.date.available2024-10-23T05:32:42Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground/Objectives: Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a new standard of care for high-risk early-stage triple-negative breast cancer (TNBC). This retrospective, multicenter study in Türkiye assessed the real-world efficacy and safety of neoadjuvant pembrolizumab combined with chemotherapy in early-stage TNBC. Methods: The study included 108 patients treated between 2021 and 2023 across 14 oncology centers. Three distinct neoadjuvant regimens incorporating pembrolizumab were administered at the discretion of the treating physicians. The primary outcomes were the pathological complete response (pCR) rate after neoadjuvant therapy and the 2-year event-free survival (EFS) and overall survival (OS) rates. Results: The observed pCR rate was 63.9%, closely mirroring the 64.8% reported in the KEYNOTE-522 trial. At the two-year mark, the EFS rate was 87.2% and the OS rate was 92.3%. Multivariable analysis identified pCR as the sole independent predictor of both EFS and OS. The safety profile was consistent with previous clinical trial data, with most adverse events being of grade 1-2 in severity. Conclusions: These findings provide valuable real-world confirmation of the efficacy and safety of neoadjuvant pembrolizumab-chemotherapy in early-stage TNBC, complementing evidence from randomized trials.en_US
dc.identifier.citationKArcı, E., Bilici, A., Bayram, B., Celayir, M., Özyurt, N., Uluc, B. O., Eken, A., Başaran, G., Demirci, U., Kemal, Y., Oruncu, M. B., Ölmez, Ö. F., Selçukbiricik, F., Korkmaz, T., Ertürk, İ., Bilgetekin, İ., Çelik, S., Türkel, A., Alkan, A., Sakin, A., Can, O., Günaldı, M., Esin, E., Yıldız, Ö. (2024). Neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study. Cancers (Basel), 16(19). 10.3390/cancers16193389en_US
dc.identifier.issn2072-6694
dc.identifier.issue19en_US
dc.identifier.scopus2-s2.0-85206571312
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4934
dc.identifier.volume16en_US
dc.identifier.wosWOS:001331766600001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKemal, Yasemin
dc.language.isoen
dc.relation.ispartofCancers (Basel)
dc.relation.isversionof10.3390/cancers16193389en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEvent-free survivalen_US
dc.subjectNeoadjuvant therapyen_US
dc.subjectOverall survivalen_US
dc.subjectPathological complete responseen_US
dc.subjectPembrolizumaben_US
dc.subjectReal worlden_US
dc.subjectSafetyen_US
dc.subjectTriple-negative breast canceren_US
dc.titleNeoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
cancers-16-03389-v2.pdf
Boyut:
943.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu